Fixed dose combination of Artesunate + Mefloquine

First new malaria treatment made in Latin America, for Latin America, South East Asia and Africa!

  • Launched in 2008.
  • Included in the Essential Medicines List (EML) and Essential Medicines List for children (EMLc) of the WHO in 2013.
  • Developed by an innovative collaboration between DNDi, Brazil and South-East Asia within the FACT Project Consortium.
  • Produced by Farmanguinhos/Fiocruz (Brazilian public pharmaceutical company).
  • The 2-in-1 combination ensures that both drugs are taken together in correct proportions.
  • Simple and Adapted Regimen for Children and Adults. As Easy as 1-2-3!
  • Once daily fixed-dose combination for three days.
  • Adapted Packaging: Three year shelf life: the longest shelf life of any FDC for malaria.
  • High compliance and low risk of resistance.
  • WHO Prequalification in September 2012.
  • February 2013: Case Study on the story of artesunate–mefloquine (ASMQ), on innovative partnerships in this collaborative approach to drug development involving international partnerships and independent funding mechanisms and how it is a powerful way to develop drugs for tropical diseases.
  • Registered in Brazil in 2008, in India in 2011, in Malaysia and Myanmar in 2012; in Tanzania in 2013; in Vietnam, Niger and Burkina Faso in 2014; in Thailand and Cambodia in 2015 and Cameroon in 2016.
  • Successful South-South technology transfer from Farmanguinhos to Cipla Ltd, India.
  • Admission of Farmanguinhos/Fiocruz to the PAHO Strategic Fund in April 2013 will allow procurement by South American national control programs.
  • Soon available in other countries in Latin America, Southeast Asia and Africa.
  • Handed over to the MMV Access and Product Management team in May 2015 to help maximize patient access – read statement.

 

More information;

ASMQ brochure, September 2012
ASMQ scientific document, September 2012
ASMQ press pack, April 2008

Read more about ASMQ project

 

 

 ASMQ News

Implementation progress

Handed over to MMV Access team

ASMQ: registered in Cameroon!

Farmanguinhos/Fiocruz admitted to PAHO Strategic Fund

Over 1.3 million treatments distributed

Recent Scientific Publications

Journal of Antimicrobial Chemotherapy, June 2014

Pharmacokinetics of co-formulated mefloquine and artesunate in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum infection in Burkina Faso
Malaria Journal, May 2014
Population pharmacokinetics of mefloquine, administered as a fixed-dose combination of artesunate-mefloquine in Indian patients for the treatment of acute uncomplicated Plasmodium falciparum malaria
Malaria Journal, December 2013
Safety, efficacy and population pharmacokinetics of fixed-dose combination of artesunate-mefloquine in the treatment of acute uncomplicated Plasmodium falciparum malaria in India